{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:03:49Z","timestamp":1740135829985,"version":"3.37.3"},"reference-count":15,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2020,8,23]]},"DOI":"10.1080\/10428194.2020.1768380","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T12:20:15Z","timestamp":1590495615000},"page":"2511-2514","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes"],"prefix":"10.1080","volume":"61","author":[{"given":"Jonathan","family":"Cohen","sequence":"first","affiliation":[{"name":"Pharmacy Services, Oregon Health & Science University, Portland, OR, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Pharmacy Services, Oregon Health & Science University, Portland, OR, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Wing","sequence":"additional","affiliation":[{"name":"Pharmacy Services, Oregon Health & Science University, Portland, OR, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3790-0478","authenticated-orcid":false,"given":"Michael C.","family":"Heinrich","sequence":"additional","affiliation":[{"name":"Portland VA Health Care System and OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"key":"CIT0001","unstructured":"Leukemia \u2013 chronic myeloid \u2013 CML guide. Cancer.Net. March; 2018; [cited 2018 Oct 10]. Available from: https:\/\/www.cancer.net\/cancer-types\/leukemia-chronic-myeloid-cml"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"CIT0003","unstructured":"National Comprehensive Cancer Network. Chronic myeloid leukemia (version 1.2019); 2018; [cited 16 Oct 2018]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25011"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-739086"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5460.5460"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.012054"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205127"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.029"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2914"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5797"},{"issue":"22","key":"CIT0013","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.V128.22.791.791","volume":"128","author":"Kumagai T","year":"2016","journal-title":"Blood"},{"key":"CIT0014","unstructured":"Chelysheva E, Petrova A, Shukhov O, et\u00a0al. First interim analysis of the Russian multicenter prospective study RU-SKI: discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia and deep molecular response. Haematologica. 2018; abstract PF374."},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00372"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2020.1768380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T10:25:09Z","timestamp":1603880709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2020.1768380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,8,23]]}},"alternative-id":["10.1080\/10428194.2020.1768380"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2020.1768380","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"type":"print","value":"1042-8194"},{"type":"electronic","value":"1029-2403"}],"subject":[],"published":{"date-parts":[[2020,5,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}